DynCorp International Awarded Contract to Support IQVIA in AstraZeneca’s Clinical Trials in the Fight Against COVID-19
GERMANTOWN, Md. (January 25, 2021) – DynCorp International (DI) was awarded a work order contract to provide facilities and services in support of IQVIA’s AstraZeneca COVID-19 prevention clinical trials.
During the 180-day period of performance, which has two optional 90-day performance periods, IQVIA RDS Inc., a global provider of clinical research services, will conduct phase III clinical trials with AstraZeneca’s long acting antibody combination – AZD7442 – at several sites throughout the U.S. Under the contract, which began Jan. 11, DI is required to construct, equip and maintain several turnkey facilities in separate locations.
“DI is proud to continue supporting research organizations in the critical fight against COVID-19.” said Senior Vice President Rob Tillery.
In November 2020, Amentum acquired DynCorp International, a provider of sophisticated aviation, logistics, training, intelligence and operational solutions in more than 30 countries worldwide. By joining forces, the combined companies are delivering enhanced capabilities for their customers, including a full suite of logistics/aviation services and solutions to support their needs anywhere, anytime. Now one of the largest providers of mission critical support services to government customers worldwide.
Amentum is a premier global technical and engineering services partner supporting critical programs of national significance across defense, security, intelligence, energy and environment. We draw from a century-old heritage of operational excellence, mission focus, and successful execution underpinned by a strong culture of safety and ethics. Headquartered in Germantown, Md., we employ more than 34,000 people in all 50 states and perform work in 105 foreign countries and territories. Visit us at amentum.com to explore how we deliver excellence for our customers’ most vital missions.